Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells. To date, five ADCs have received market approval and over 100 are being investigated in various stages of clinical development. In this Therapeutics paper, we review recent clinical experience with the approved ADCs and other promising late-stage candidates on the horizon, following an overview of the biology and chemistry of ADCs and how the individual components of an ADC (antibody [or target], linker and conjugation chemistry, and cytotoxic payload) influence its activity. We briefly discuss opportunities for enhancing ADC efficacy, drug resistance, and future perspectives for this novel antibody-based molecular platform, which has great potential to make a paradigm shift in cancer chemotherapy.

中文翻译：

---

抗体-药物偶联物用于癌症

抗体-药物偶联物（ADC）是免疫偶联物，由通过化学接头与细胞毒性药物（称为有效负载）拴在一起的单克隆抗体组成。ADC旨在选择性地将超毒性有效载荷直接传递至目标癌细胞。迄今为止，已有五个ADC获得市场认可，并且正在临床开发的各个阶段对100多个ADC进行研究。在本治疗论文中，我们概述了ADC的生物学和化学特性以及ADC的各个成分（抗体[或靶标]，接头和偶联化学，以及细胞毒性有效载荷）影响其活性。我们简要讨论了提高ADC疗效，耐药性，